BioSpace News Archive

Quantzig, a leading analytics advisory firm that delivers customized analytics solutions, has announced the completion of its free resource that highlights how sales force effectiveness is reinventing the pharma industry in the United States.

The patient lifting devices market is expected to post a CAGR close to 8% during the period 2019-2023, according to the latest market research report by Technavio.

New SCAPE 2.0 system can serve as a critical tool to advance science and medicine

The U.S. Food and Drug Administration approved Rituxan injection to treat granulomatosis with polyangiitis and microscopic polyangiitis in children 2 years of age and older in combination with glucocorticoids.

The American Society of Cannabis Medicine announced that members of its leadership have been asked to participate at the Second Annual Update on Medical Cannabis Friday, Sept. 27 presented by the Department of Psychiatry and Behavioral Sciences of the Medical University of South Carolina.

Lannett Company, Inc. announced the closing of $86.25 million aggregate principal amount of 4.50% convertible senior notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events

Acacia Diversified Holdings, Inc., www.acaciadiversifiedholdings.com an emerging cannabis company, is announcing its receipt of its second food grade manufactures permit in the company’s mobile fleet.

X4 Pharmaceuticals, Inc. announced that, on September 27, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

EMD Serono and Pfizer Inc. announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® alone or as part of combination regimens for the treatment of advanced cancers, including renal cell carcinoma, metastatic Merkel cell carcinoma and some other solid tumors at the European Society for Medical Oncology Congress 2019 in Barcelona, Spain.